This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CASI Pharmaceuticals, Inc.
Drug Names(s): ENMD2076
Description: ENMD-2076 is a novel, selective kinase inhibitor with potent activityagainst Aurora A and tyrosine kinases linked to the promotion of cancer andinflammatory diseases. ENMD-2076 acts through multiple pathways resulting inantiproliferative activity and the inhibition of angiogenesis. ENMD-2076 hasdemonstrated substantial, dose-dependent efficacy as a single agent inmultiple preclinical models, including tumor regression in breast, colon, andleukemia models. Importantly, ENMD-2076 is an oral agent that has shown anacceptable toxicity profile in preclinical studies without cardiovasculartoxicity.
EntreMed and Miikana
In January 2006, EntreMed acquired Miikana Therapeutics and as a result of the transaction, added ENMD-2076 to its pipeline.
EntreMed and Selected Value Therapeutics
In June 2011, EntreMed announced that Selected Value Therapeutics I, LLC (SVT) has exercised its right to acquire an exclusive license to develop and commercialize ENMD-2076 in China and certain of its territories. EntreMed retains development and commercialization rights to ENMD-2076 in the rest of the world. Under the terms of the agreement, EntreMed is entitled to certain development milestone payments, as well as royalties on future product sales within the geographic market. SVT will be responsible for all clinical development and regulatory costs related to regulatory approval in the China territory. On February 1, 2012, the parties mutually agreed to amend the China Rights Agreement to extend the termination date from January 31, 2012 to March 31, 2012 to permit the...See full deal structure in Biomedtracker
Additional information available to subscribers only: